A Phase 2 interventional study of AC220 in Leukemia, Myeloid, Acute, sponsored by Daiichi Sankyo. Completed at 24 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-27.
Sponsored by Daiichi Sankyo · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.
Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 12th largest by enrollment, is one of 2 that started in 2012, is one of 7 in phase 2, and was the 5th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:
PETHEMA Foundation · Sites in Spain
Ages 18+
Daiichi Sankyo · Sites in United States, Australia, Brazil and 2 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18+
Princess Maxima Center for Pediatric Oncology · Sites in Netherlands
Ages 1 mo–18 yrs
Kura Oncology, Inc. · Sites in United States
Ages 18+
By country, each count listing its studies:
quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 15 · Phase 3 5
First in 2007; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 76 is above the median of 40 across 3,006 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 69 across the 28 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
21 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo: 1 open now, 3 under way, 1 of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 21 studies in Leukemia, Myeloid, Acute by Daiichi Sankyo, this one is the 7th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2012, is one of 4 in phase 2, and was the 7th registered.
Daiichi Sankyo’s Leukemia, Myeloid, Acute studies by the year they started, since 1999.
1 of the studies testing quizartinib in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03793478Daiichi SankyoSafety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Daiichi Sankyo’s 21 in Leukemia, Myeloid, Acute:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate two doses of Quizartinib in patients with relapsed or refractory acute myeloid leukemia who are also FMS-like tyrosine kinase - internal tandem duplication ( FLT3-ITD) positive. Patient will be randomly assigned in a 1:1 ratio to one of two treatment arms. Both treatment arms will receive Quizartinib but at different doses. The study treatment is taken orally in 28 day cycles until either disease progression occurs or an unacceptable toxicity occurs. In addition to the study assessments to evaluate the disease, blood will be drawn to measure drug levels and biomarkers. Patients will be followed for survival at three month intervals after the end of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AC220
Drug: AC220
oral
Also known as: Quizartinib, ASP2689
Number of Participants Who Achieved Composite Complete Response (CRc) (Intent-to-Treat Population)
CRc is defined as Complete remission (CR) + Complete remission with incomplete platelet recovery (CRp) + Complete remission with incomplete hematological recovery (CRi). * Participants with CR must have normal hematopoietic cells and achieved a morphologic leukemia-free state (\<5% bone marrow blasts in bone marrow, no blasts with Auer rods and no persistence of extramedullary disease) and must have had an absolute neutrophil count (ANC) ≥1 × 10\^9/L and platelet count ≥100 × 10\^9/L and were red blood cell (RBC) and platelet transfusion independent. Blasts in the peripheral blood was to be ≤1% (if blood sample was available). * Participants with CRp must have achieved CR except for incomplete platelet recovery (\< 100 ×10\^9/L). * Participants with CRi must have fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \<1 × 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence were not required.
Time frame: At end of Cycle 2 (after two complete 28-day cycles post treatment)
Number of Participants Who Achieved Complete Remission (CR) (Intent-to-Treat Population)
Participant must have bone marrow regenerating normal hematopoietic cells and achieve a morphologic leukemia-free state (\< 5% bone marrow blasts in bone marrow, no blasts with Auer rods and no persistence of extramedullary disease) and must have an absolute neutrophil count (ANC) ≥ 1x10\^9/L and platelet count ≥ 100 x 10\^9/L and they will be red blood cell (RBC) and platelet transfusion independent (defined as 4 weeks without RBC transfusions and 1 week without platelet transfusion).
Time frame: At end of treatment visit (approximately 3 years post treatment)
Overall Survival (OS) After Approximately 3 Years (Intent-to-Treat Population)
OS was defined as the time from the date of randomization until the date of death from any cause.
Time frame: Evaluated at end of study, up to 6 months (approximately 3 years post treatment)
Event Free Survival (EFS) After Approximately 3 Years (Intent-to-Treat Population)
EFS was defined as the time from the date of randomization until the date of documented relapse or death.
Time frame: Evaluated at end of study, up to 6 months (approximately 3 years post treatment)
Leukemia Free Survival (LFS) After Approximately 3 Years (Intent-to-Treat Population)
LFS was defined as the time from the date of first CRc until the date of documented relapse or death for participants who achieved CRc.
Time frame: Evaluated at end of study, up to 6 months (approximately 3 years post treatment)
Duration of Remission After Approximately 3 Years (Intent-to-Treat Population)
Duration of remission was defined as the time from first documented remission until documented relapse. CRc was defined as composite complete remission and CRi was defined as complete remission with incomplete hematological recovery.
Time frame: Evaluated at end of study, up to 6 months (approximately 3 years post treatment)
Time to Composite Complete Remission (CRc) in Participants Who Achieved CRc After Approximately 3 Years (Intent-to-Treat Population)
Time to CRc was defined as the time from the date of randomization until the first disease assessment of CRc. Time to CRc was only evaluated in participants who achieved CRc.
Time frame: Evaluated at end of study, up to 6 months (approximately 3 years post treatment)
Percentage of Participants Undergoing Hematopoietic Stem Cell Transplantation (HSCT) After Approximately 3 Years (Intent-to-Treat Population)
Transplantation rate was defined as the percentage of participants who underwent HSCT directly after treatment with quizartinib (no other intervening acute myeloid leukemia therapies other than conditioning regimens for the HSCT).
Time frame: Evaluated at end of study, up to 6 months (approximately 3 years post treatment)
Percentage of Participants With Grade 2 or Higher QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) Prolongation After Receiving Quizartinib (Safety Analysis Set)
QT interval corrected for heart rate using Fridericia's formula (QTcF) grading was to be done according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 and the definition of Grade 2 or higher prolongation is QTcF more than 480 msec.
Time frame: Evaluated at end of study, up to 6 months (approximately 3 years post treatment)
A total of 76 participants who met all inclusion criteria and no exclusion criteria were enrolled in the study (intent-to-treat population). Participants were enrolled at 22 clinic sites in North America and Europe (14 sites in the United States, 6 in France, 1 in Italy, and 1 in the United Kingdom).
| Milestone | Quizartinib 30 mg | Quizartinib 60 mg |
|---|---|---|
| Started | 38 | 38 |
| Completed treatment per protocol | 0 | 0 |
| Started 30-day follow-up | 37 | 37 |
| Completed 30-day follow-up | 11 | 5 |
| Started long-term follow-up | 36 | 33 |
| Completed long-term follow-up | 0 | 0 |
| Completed | 0 | 0 |
| Not completed | 38 | 38 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Lack of efficacy | 4 | 2 |
| Withdrew: Participant went on hospice care | 1 | 0 |
| Withdrew: Adverse event | 6 | 1 |
| Withdrew: Randomized, but never received drug | 0 | 2 |
| Withdrew: Progressive disease | 13 | 14 |
| Withdrew: Withdrawal by subject | 1 | 3 |
| Withdrew: Hsct transplant | 11 | 15 |
CRc is defined as Complete remission (CR) + Complete remission with incomplete platelet recovery (CRp) + Complete remission with incomplete hematological recovery (CRi). * Participants with CR must have normal hematopoietic cells and achieved a morphologic leukemia-free state (\<5% bone marrow blasts in bone marrow, no blasts with Auer rods and no persistence of extramedullary disease) and must have had an absolute neutrophil count (ANC) ≥1 × 10\^9/L and platelet count ≥100 × 10\^9/L and were red blood cell (RBC) and platelet transfusion independent. Blasts in the peripheral blood was to be ≤1% (if blood sample was available). * Participants with CRp must have achieved CR except for incomplete platelet recovery (\< 100 ×10\^9/L). * Participants with CRi must have fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \<1 × 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence were not required.
| Participants | Quizartinib 30 mg | Quizartinib 60 mg |
|---|---|---|
| Number of Participants Who Achieved Composite Complete Response (CRc) (Intent-to-Treat Population) | 18 | 18 |
Participant must have bone marrow regenerating normal hematopoietic cells and achieve a morphologic leukemia-free state (\< 5% bone marrow blasts in bone marrow, no blasts with Auer rods and no persistence of extramedullary disease) and must have an absolute neutrophil count (ANC) ≥ 1x10\^9/L and platelet count ≥ 100 x 10\^9/L and they will be red blood cell (RBC) and platelet transfusion independent (defined as 4 weeks without RBC transfusions and 1 week without platelet transfusion).
| Participants | Quizartinib 30 mg | Quizartinib 60 mg |
|---|---|---|
| Number of Participants Who Achieved Complete Remission (CR) (Intent-to-Treat Population) | 2 | 1 |
OS was defined as the time from the date of randomization until the date of death from any cause.
| weeks | Quizartinib 30 mg | Quizartinib 60 mg |
|---|---|---|
| Overall Survival (OS) After Approximately 3 Years (Intent-to-Treat Population) | 20.9 (17.7 to 25.3) | 27.3 (17.3 to 34.9) |
EFS was defined as the time from the date of randomization until the date of documented relapse or death.
| weeks | Quizartinib 30 mg | Quizartinib 60 mg |
|---|---|---|
| Event Free Survival (EFS) After Approximately 3 Years (Intent-to-Treat Population) | 12.0 (8.3 to 16.1) | 13.7 (9.7 to 26.1) |
LFS was defined as the time from the date of first CRc until the date of documented relapse or death for participants who achieved CRc.
| weeks | Quizartinib 30 mg | Quizartinib 60 mg |
|---|---|---|
| Leukemia Free Survival (LFS) After Approximately 3 Years (Intent-to-Treat Population) | 4.1 (2.1 to 9.7) | 9.1 (4.0 to 22.3) |
Duration of remission was defined as the time from first documented remission until documented relapse. CRc was defined as composite complete remission and CRi was defined as complete remission with incomplete hematological recovery.
| weeks | Quizartinib 30 mg | Quizartinib 60 mg |
|---|---|---|
| CRc | 4.2 (2.1 to 9.7) | 9.1 (4.1 to 22.3) |
| CRi | 4.1 (2.1 to 9.7) | 20.0 (4.0 to 75.6) |
Time to CRc was defined as the time from the date of randomization until the first disease assessment of CRc. Time to CRc was only evaluated in participants who achieved CRc.
| weeks | Quizartinib 30 mg | Quizartinib 60 mg |
|---|---|---|
| Time to Composite Complete Remission (CRc) in Participants Who Achieved CRc After Approximately 3 Years (Intent-to-Treat Population) | 4.4 (4.1 to 7.7) | 4.6 (4.1 to 8.0) |
Transplantation rate was defined as the percentage of participants who underwent HSCT directly after treatment with quizartinib (no other intervening acute myeloid leukemia therapies other than conditioning regimens for the HSCT).
| percentage of participants | Quizartinib 30 mg | Quizartinib 60 mg |
|---|---|---|
| Yes | 31.6 | 42.1 |
| No | 68.4 | 55.3 |
| Unknown | 0 | 2.6 |
QT interval corrected for heart rate using Fridericia's formula (QTcF) grading was to be done according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 and the definition of Grade 2 or higher prolongation is QTcF more than 480 msec.
| percentage of participants | Quizartinib 30 mg | Quizartinib 60 mg |
|---|---|---|
| Max on study; <450 msec | 47.4 | 36.1 |
| Max on study; ≥450 msec and ≤480 msec | 42.1 | 47.2 |
| Max on study; >480 msec and ≤500 msec | 5.3 | 13.9 |
| Max on study; >500 msec | 5.3 | 2.8 |
| Max change from baseline; ≤30 msec | 47.4 | 38.9 |
| Max change from baseline; >30 msec and ≤60 msec | 47.4 | 41.7 |
| Max change from baseline; >60 msec | 5.3 | 19.4 |
Collected over Adverse event data were collected from the first dose of treatment up to 30 days from the last dose of treatment in the safety analysis set. Two participants in the quizartinib 60 mg cohort did not receive the study drug and were not included in the safety analysis set.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Quizartinib 30 mg | 9/38 (23.7%) | 25/38 (65.8%) | 37/38 (97.4%) |
| Quizartinib 60 mg | 13/36 (36.1%) | 23/36 (63.9%) | 36/36 (100%) |
| Event | Quizartinib 30 mg | Quizartinib 60 mg |
|---|---|---|
| Acute myeloid leukemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/38 | 7/36 |
| Febrile neutropeniaBlood and lymphatic system disorders | 7/38 | 6/36 |
| PneumoniaInfections and infestations | 3/38 | 6/36 |
| PyrexiaGeneral disorders | 3/38 | 5/36 |
| NauseaGastrointestinal disorders | 0/38 | 2/36 |
| VomitingGastrointestinal disorders | 0/38 | 2/36 |
| Multi-organ failureGeneral disorders | 0/38 | 2/36 |
| CellulitisInfections and infestations | 1/38 | 2/36 |
| Septic shockInfections and infestations | 1/38 | 2/36 |
| Alanine aminotransferase increasedInvestigations | 0/38 | 2/36 |
| Event | Quizartinib 30 mg | Quizartinib 60 mg |
|---|---|---|
| AnemiaBlood and lymphatic system disorders | 18/38 | 9/36 |
| NauseaGastrointestinal disorders | 10/38 | 17/36 |
| PyrexiaGeneral disorders | 11/38 | 14/36 |
| Febrile neutropeniaBlood and lymphatic system disorders | 12/38 | 13/36 |
| VomitingGastrointestinal disorders | 11/38 | 13/36 |
| DiarrheaGastrointestinal disorders | 10/38 | 13/36 |
| FatigueGeneral disorders | 13/38 | 8/36 |
| Abdominal painGastrointestinal disorders | 6/38 | 11/36 |
| ThrombocytopeniaBlood and lymphatic system disorders | 10/38 | 7/36 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/38 | 9/36 |
| Age, Continuous(years) | Quizartinib 30 mg | Quizartinib 60 mg | Total |
|---|---|---|---|
| Median | 56.5 (19 to 77) | 53.0 (20 to 74) | 54.5 (19 to 77) |
| Sex: Female, Male(Participants) | Quizartinib 30 mg | Quizartinib 60 mg | Total |
|---|---|---|---|
| Female | 16 | 16 | 32 |
| Male | 22 | 22 | 44 |
| Race (NIH/OMB)(Participants) | Quizartinib 30 mg | Quizartinib 60 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 3 |
| White | 29 | 30 | 59 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 4 | 11 |
| Region of Enrollment(participants) | Quizartinib 30 mg | Quizartinib 60 mg | Total |
|---|---|---|---|
| United States | 29 | 29 | 58 |
| Italy | 0 | 3 | 3 |
| United Kingdom | 2 | 1 | 3 |
| France | 7 | 5 | 12 |
Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
The record gives a start of Apr 2012, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2019, 4 years 9 months after primary completion. A results delay was requested in Apr 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Quizartinib